Propranolol precautions

List of precautions
General Clinical Laboratory Tests Drug Interactions Cardiovascular Drugs Antiarrhythmics Digitalis Glycosides Calcium Channel Blockers ACE Inhibitors Alpha Blockers Reserpine Inotropic Agents Non-Cardiovascular Drugs Nonsteroidal Anti-Inflammatory Drugs Antidepressants Anesthetic Agents Warfarin Neuroleptic Drugs Thyroxine Carcinogenesis, Mutagenesis, Impairment of Fertility Pregnancy Nursing mothers Pediatric use Geriatric use

General
Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol hydrochloride extended-release is not indicated for the treatment of hypertensive emergencies.

Beta-adrenergic receptor blockade can cause reduction of intraocular pressure. Patients should be told that Propranolol hydrochloride extended-release may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Return to top

Clinical Laboratory Tests
In patients with hypertension, use of Propranolol has been associated with elevated levels of serum potassium, serum transaminases, and alkaline phosphatase. In severe heart failure, the use of Propranolol has been associated with increases in Blood Urea Nitrogen. Return to top

Drug Interactions
Caution should be exercised when Propranolol hydrochloride extended-release is administered with drugs that have an affect on CYP2D6, 1A2, or 2C19 metabolic pathways. Co-administration of such drugs with Propranolol may lead to clinically relevant drug interactions and changes on its efficacy and/or toxicity.

Alcohol when used concomitantly with Propranolol, may increase plasma levels of Propranolol. Return to top

Antiarrhythmics
Propafenone has negative inotropic and beta-blocking properties that can be additive to those of Propranolol.

Quinidine increases the concentration of Propranolol and produces greater degrees of clinical beta-blockade and may cause postural hypotension.

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with β-blockers such as Propranolol.

The clearance of lidocaine is reduced with administration of Propranolol. Lidocaine toxicity has been reported following co-administration with Propranolol.

Caution should be exercised when administering Propranolol hydrochloride extended-release with drugs that slow A-V nodal conduction, e.g., lidocaine and calcium channel blockers.

Return to top

Digitalis Glycosides
Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Return to top

Calcium Channel Blockers
Caution should be exercised when patients receiving a beta-blocker are administered a calcium channel-blocking drug with negative inotropic and/or chronotropic effects. Both agents may depress myocardial contractility or atrioventricular conduction.

There have been reports of significant bradycardia, heart failure, and cardiovascular collapse with concurrent use of verapamil and beta-blockers.

Co-administration of Propranolol and diltiazem in patients with cardiac disease has been associated with bradycardia, hypotension, high degree heart block, and heart failure.

Return to top

ACE Inhibitors
When combined with beta-blockers, ACE inhibitors can cause hypotension, particularly in the setting of acute myocardial infarction.

The antihypertensive effects of clonidine may be antagonized by beta-blockers. Propranolol hydrochloride extended-release should be administered cautiously to patients withdrawing from clonidine.

Return to top

Alpha Blockers
Prazosin has been associated with prolongation of first dose hypotension in the presence of beta-blockers.

Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin.

Return to top

Reserpine
Patients receiving catecholamine-depleting drugs, such as reserpine should be closely observed for excessive reduction of resting sympathetic nervous activity, which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Return to top

Inotropic Agents
Patients on long-term therapy with Propranolol may experience uncontrolled hypertension if administered epinephrine as a consequence of unopposed alpha-receptor stimulation. Epinephrine is therefore not indicated in the treatment of Propranolol overdose.

Isoproterenol and Dobutamine

Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol.

Also, Propranolol may reduce sensitivity to dobutamine stress echocardiography in patients undergoing evaluation for myocardial ischemia.

Return to top

Nonsteroidal Anti-Inflammatory Drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to blunt the antihypertensive effect of beta-adrenoreceptor blocking agents.

Administration of indomethacin with Propranolol may reduce the efficacy of Propranolol in reducing blood pressure and heart rate.

Antidepressants
The hypotensive effects of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers by interfering with the beta blocking activity of Propranolol.

Anesthetic Agents
Methoxyflurane and trichloroethylene may depress myocardial contractility when administered with Propranolol.

Return to top

Warfarin
Propranolol when administered with warfarin increases the concentration of warfarin. Prothrombin time, therefore, should be monitored.

Return to top

Neuroleptic Drugs
Hypotension and cardiac arrest have been reported with the concomitant use of Propranolol and haloperidol.

Return to top

Thyroxine
Thyroxine may result in a lower than expected T3 concentration when used concomitantly with Propranolol.

Return to top

Carcinogenesis, Mutagenesis, Impairment of Fertility
In dietary administration studies in which mice and rats were treated with Propranolol hydrochloride for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis.

On a body surface area basis, this dose in the mouse and rat is, respectively, about equal to and about twice the maximum recommended human oral daily dose (MRHD) of 640 mg Propranolol hydrochloride.

In a study in which both male and female rats were exposed to Propranolol hydrochloride in their diets at concentrations of up to 0.05% (about 50 mg/kg body weight and less than the MRHD), from 60 days prior to mating and throughout pregnancy and lactation for two generations, there were no effects on fertility.

Based on differing results from Ames Tests performed by different laboratories, there is equivocal evidence for a genotoxic effect of Propranolol in bacteria (S. typhimurium strain TA 1538).

Return to top

Pregnancy
Pregnancy: Category C

In a series of reproductive and developmental toxicology studies, Propranolol was given to rats by gavage or in the diet throughout pregnancy and lactation. At doses of 150 mg/kg/day, but not at doses of 80 mg/kg/day (equivalent to the MRHD on a body surface area basis), treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (deaths). Propranolol hydrochloride also was administered (in the feed) to rabbits (throughout pregnancy and lactation) at doses as high as 150 mg/kg/day (about 5 times the maximum recommended human oral daily dose). No evidence of embryo or neonatal toxicity was noted.

There are no adequate and well-controlled studies in pregnant women.

Intrauterine growth retardation, small placentas, and congenital abnormalities have been reported in neonates whose mothers received Propranolol during pregnancy. Neonates whose mothers are receiving Propranolol at parturition have exhibited bradycardia, hypoglycemia and/or respiratory depression. Adequate facilities for monitoring such infants at birth should be available. Propranolol hydrochloride extended-release should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Return to top

Nursing Mothers
Propranolol is excreted in human milk. Caution should be exercised when Propranolol hydrochloride extended-release is administered to a nursing woman.

Return to top

Pediatric Use
Safety and effectiveness of Propranolol in pediatric patients have not been established.

Bronchospasm and congestive heart failure have been reported coincident with the administration of Propranolol therapy in pediatric patients.

Return to top

Geriatric Use
Clinical studies of Propranolol hydrochloride extended-release did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of the decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Return to top